Biocon and Sandoz, a division of Swiss-pharmaceutical major Novartis, on Thursday said they have entered into a global partnership to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients across the globe.
Throwing further light on the above tie-up, Kiran Mazumdar Shaw, CMD, Biocon told CNBC-TV18 that biosimilars is the generics opportunity of the future and partnership with Sandoz is for the future wave of biosimilars.
“Both partners will develop select number of assets from end to end and allows Biocon to start front-ending some of the activities – such as getting market authorisation in their name,” she said.
Furthermore, she said Sandoz is responsible for commercializing in the US and European markets and Biocon has the rest of the world market including developed markets like Japan, Australia, New Zealand.
Therefore, the partners will share the development costs and profits equally, said Mazumdar Shaw.
She also clarified that Sandoz and Mylan are exclusive relationships, adding that they have excellent relationship with Mylan and the partnership is developing a number of biosimilar assets. Both hope to expand the partnership, she said. Similarly, they also hope to expand the Sandoz partnership.
The investment cost could be north of USD 100 million apiece (biosimilar) to develop, she said.
In the foreseeable future, she said Biocon would be a significant player in the biosimilar opportunity and that is the reason they have entered into such partnership.
She said, the company is trying to combine forces with companies who have been successful in biosimilars.
With regards to Bengaluru plant, she said they are ready of re-inspection by European Medicines Agency and is confident of passing the inspection.